California Public Employees Retirement System lifted its holdings in shares of SIGA Technologies, Inc. (OTCMKTS:SIGA) by 72.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 28,080 shares of the biotechnology company’s stock after purchasing an additional 11,840 shares during the quarter. California Public Employees Retirement System’s holdings in SIGA Technologies were worth $144,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. BlackRock Inc. increased its position in SIGA Technologies by 17.8% during the second quarter. BlackRock Inc. now owns 4,134,540 shares of the biotechnology company’s stock worth $23,485,000 after purchasing an additional 626,084 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of SIGA Technologies during the 2nd quarter valued at $1,914,000. AltraVue Capital LLC grew its stake in shares of SIGA Technologies by 13.4% during the 2nd quarter. AltraVue Capital LLC now owns 2,269,113 shares of the biotechnology company’s stock valued at $12,888,000 after buying an additional 268,106 shares during the period. Vanguard Group Inc. increased its holdings in shares of SIGA Technologies by 5.7% during the 2nd quarter. Vanguard Group Inc. now owns 2,681,237 shares of the biotechnology company’s stock worth $15,230,000 after buying an additional 143,831 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of SIGA Technologies during the 2nd quarter worth $636,000. Institutional investors and hedge funds own 6.66% of the company’s stock.
Shares of SIGA opened at $4.43 on Friday. SIGA Technologies, Inc. has a twelve month low of $4.30 and a twelve month high of $8.09. The stock’s fifty day simple moving average is $5.24 and its 200 day simple moving average is $5.39.
SIGA Technologies Company Profile
SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).
Featured Article: Earnings Per Share
Want to see what other hedge funds are holding SIGA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SIGA Technologies, Inc. (OTCMKTS:SIGA).
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.